Welcome to the podcast series CAN-R3: Canadian Initiative to Reduce Residual Risk – Game Changers in Dyslipidemia Management. In this series, Canadian experts discuss the importance and challenges of reducing LDL-C in patients with established ASCVD, recommendations from the 2021 Canadian Cardiovascular Society Guidelines, and evidence around statins efficacy and adherence in different patient populations. Visit iMedicus.ca/Dyslipidemia to watch the Section 1 accredited webinars.
 
In this first episode, Dr. Judy Luu and Dr. Shaun Goodman exchange on the different contributors to residual risk, the role of LDL-C in atherosclerosis, the importance of reducing LDL-C as low as possible, identifying patients who benefit the most from intensification therapy beyond statins, and the shift to LDL-C thresholds as opposed to treatment targets.

Updates to the CCS Dyslipidemia Guidelines: Application to Established CVD Patients

iMedicus Cardiology, presented by EOCI Pharmacomm, features short and engaging episodes for Canadian Health Care Professionals practicing in cardiology.  Tune in for the latest on guidelines, current and emerging therapies, clinical pearls, and best practices, across a range of topics in Cardiology.